138 related articles for article (PubMed ID: 33408093)
1. Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Hao X; Falo Iii LD; Chen G; Zhang J; Carey CD; Storkus WJ; Falo LD; You Z
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33408093
[TBL] [Abstract][Full Text] [Related]
2. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
3. Androgen receptor is a determinant of melanoma targeted drug resistance.
Samarkina A; Youssef MK; Ostano P; Ghosh S; Ma M; Tassone B; Proust T; Chiorino G; Levesque MP; Goruppi S; Dotto GP
Nat Commun; 2023 Oct; 14(1):6498. PubMed ID: 37838724
[TBL] [Abstract][Full Text] [Related]
4. Combination immunotherapy including OncoVEX
Gartrell RD; Blake Z; Rizk EM; Perez-Lorenzo R; Weisberg SP; Simoes I; Esancy C; Fu Y; Davari DR; Barker L; Finkel G; Mondal M; Minns HE; Wang SW; Fullerton BT; Lozano F; Chiuzan C; Horst B; Saenger YM
Cancer Immunol Immunother; 2022 Aug; 71(8):1837-1849. PubMed ID: 34999916
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas.
Zeng Z; Ngo HL; Proctor M; Rizos H; Dolcetti R; Cruz JG; Wells JW; Gabrielli B
Pigment Cell Melanoma Res; 2024 Jan; 37(1):45-50. PubMed ID: 37614154
[TBL] [Abstract][Full Text] [Related]
6. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer.
Marelli G; Chard Dunmall LS; Yuan M; Di Gioia C; Miao J; Cheng Z; Zhang Z; Liu P; Ahmed J; Gangeswaran R; Lemoine N; Wang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33500259
[TBL] [Abstract][Full Text] [Related]
7. S-adenosylmethionine blocks tumorigenesis and with immune checkpoint inhibitor enhances anti-cancer efficacy against BRAF mutant and wildtype melanomas.
Mehdi A; Attias M; Arakelian A; Szyf M; Piccirillo CA; Rabbani SA
Neoplasia; 2023 Feb; 36():100874. PubMed ID: 36638586
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Haspin Kinase Promotes Cell-Intrinsic and Extrinsic Antitumor Activity.
Melms JC; Vallabhaneni S; Mills CE; Yapp C; Chen JY; Morelli E; Waszyk P; Kumar S; Deming D; Moret N; Rodriguez S; Subramanian K; Rogava M; Cartwright ANR; Luoma A; Mei S; Brinker TJ; Miller DM; Spektor A; Schadendorf D; Riggi N; Wucherpfennig KW; Sorger PK; Izar B
Cancer Res; 2020 Feb; 80(4):798-810. PubMed ID: 31882401
[TBL] [Abstract][Full Text] [Related]
9. Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma.
Kim J; Archer PA; Manspeaker MP; Avecilla ARC; Pollack BP; Thomas SN
J Control Release; 2023 May; 357():655-668. PubMed ID: 37080489
[TBL] [Abstract][Full Text] [Related]
10. The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.
Wu M; Hanly A; Gibson F; Fisher R; Rogers S; Park K; Zuger A; Kuang K; Kalin JH; Nocco S; Cole M; Xiao A; Agus F; Labadorf A; Beck S; Collard M; Cole PA; Alani RM
J Clin Invest; 2024 Feb; 134(6):. PubMed ID: 38300709
[TBL] [Abstract][Full Text] [Related]
11. Molecular patterns of resistance to immune checkpoint blockade in melanoma.
Lauss M; Phung B; Borch TH; Harbst K; Kaminska K; Ebbesson A; Hedenfalk I; Yuan J; Nielsen K; Ingvar C; Carneiro A; Isaksson K; Pietras K; Svane IM; Donia M; Jönsson G
Nat Commun; 2024 Apr; 15(1):3075. PubMed ID: 38594286
[TBL] [Abstract][Full Text] [Related]
12. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
13. Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma.
Augustin RC; Luke JJ
Am J Clin Dermatol; 2024 May; 25(3):421-434. PubMed ID: 38409643
[TBL] [Abstract][Full Text] [Related]
14. Global pannexin 1 deletion increases tumor-infiltrating lymphocytes in the BRAF/Pten mouse melanoma model.
Sanchez-Pupo RE; Finch GA; Johnston DE; Craig H; Abdo R; Barr K; Kerfoot S; Dagnino L; Penuela S
Mol Oncol; 2024 Apr; 18(4):969-987. PubMed ID: 38327091
[TBL] [Abstract][Full Text] [Related]
15. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance.
Orgaz JL; Crosas-Molist E; Sadok A; Perdrix-Rosell A; Maiques O; Rodriguez-Hernandez I; Monger J; Mele S; Georgouli M; Bridgeman V; Karagiannis P; Lee R; Pandya P; Boehme L; Wallberg F; Tape C; Karagiannis SN; Malanchi I; Sanz-Moreno V
Cancer Cell; 2020 Jan; 37(1):85-103.e9. PubMed ID: 31935375
[TBL] [Abstract][Full Text] [Related]
16. Histone Deacetylase Inhibition Sensitizes PD1 Blockade-Resistant B-cell Lymphomas.
Wang X; Waschke BC; Woolaver RA; Chen Z; Zhang G; Piscopio AD; Liu X; Wang JH
Cancer Immunol Res; 2019 Aug; 7(8):1318-1331. PubMed ID: 31235619
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy.
Zhu Z; Tang R; Huff S; Kummetha IR; Wang L; Li N; Rana TM
Cancer Res Commun; 2023 Jan; 3(1):119-129. PubMed ID: 36968224
[TBL] [Abstract][Full Text] [Related]
18. Unlocking PD-1 antibody resistance: The MUC1 DNA vaccine augments CD8
Wang X; Miao Y; Shen J; Li D; Deng X; Yang C; Ji Y; Dai Z; Ma Y
Scand J Immunol; 2024 May; 99(5):e13356. PubMed ID: 38605549
[TBL] [Abstract][Full Text] [Related]
19. CD38-RyR2 axis-mediated signaling impedes CD8
Kar A; Ghosh P; Gautam A; Chowdhury S; Basak D; Sarkar I; Bhoumik A; Barman S; Chakraborty P; Mukhopadhyay A; Mehrotra S; Ganesan SK; Paul S; Chatterjee S
Proc Natl Acad Sci U S A; 2024 Mar; 121(11):e2315989121. PubMed ID: 38451948
[TBL] [Abstract][Full Text] [Related]
20. T-Type Calcium Channels: A Potential Novel Target in Melanoma.
Barceló C; Sisó P; Maiques O; de la Rosa I; Martí RM; Macià A
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32046241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
